Hookipa Pharma (HOOK) News Today $1.78 -0.03 (-1.66%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.80 +0.01 (+0.84%) As of 02/21/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)February 20 at 3:06 PM | globenewswire.comHookipa Pharma Drops Poolbeg Takeover BidFebruary 20 at 2:01 PM | marketwatch.comHOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)February 20 at 11:42 AM | globenewswire.comHookipa Pharma stock hits 52-week low at $1.71 amid downturnFebruary 11, 2025 | msn.comHookipa Pharma announces enrollment completion of Phase 1b HB-500 trialJanuary 31, 2025 | finance.yahoo.comHOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIVJanuary 30, 2025 | markets.businessinsider.comHOOKIPA Pharma seeks court validation for stockholder actionsJanuary 29, 2025 | msn.comForm 8.3 - HOOKIPA Pharma Inc.January 15, 2025 | finance.yahoo.comHookipa Pharma (HOOK) was downgraded to a Hold Rating at CitiJanuary 12, 2025 | markets.businessinsider.comHC Wainwright & Co. Downgrades HOOKIPA Pharma (HOOK)January 11, 2025 | msn.comHookipa Pharma downgraded to Neutral from Buy at H.C. WainwrightJanuary 10, 2025 | markets.businessinsider.comPoolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPAJanuary 10, 2025 | globenewswire.comHOOKIPA Pharma Inc - FORM 8 (OPD)January 8, 2025 | globenewswire.comHOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure RequirementsJanuary 7, 2025 | globenewswire.comPoolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPAJanuary 7, 2025 | globenewswire.comHOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – AmendmentJanuary 6, 2025 | globenewswire.comDeal Dispatch: Vera Bradley Is A Mixed Bag, Modell's Ex-CEO Explores Party CityJanuary 3, 2025 | benzinga.comCathal Friel’s Poolbeg Pharma plunges on merger talks that would see listing move to NasdaqJanuary 3, 2025 | msn.comPoolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.January 2, 2025 | globenewswire.comRBC Capital Downgrades HOOKIPA Pharma (HOOK)December 21, 2024 | msn.comRBC downgrades Hookipa, slashes price targetDecember 20, 2024 | msn.comEnanta Pharmaceuticals’ RSV Platform Advances: Buy Rating Affirmed on Promising Clinical DataDecember 10, 2024 | markets.businessinsider.comHOOKIPA Pharma's SWOT analysis: stock faces challenges amid pipeline shiftsNovember 27, 2024 | uk.investing.comHookipa Pharma price target lowered to $7 from $24 at JMP SecuritiesNovember 22, 2024 | finance.yahoo.comHookipa Pharma announces workforce reduction of 80%, pause of eseba-vec programNovember 21, 2024 | markets.businessinsider.comStrategic Shift and Partnership Potential Drive Buy Rating for HOOKIPA PharmaNovember 21, 2024 | markets.businessinsider.comCompanies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite RiskyNovember 17, 2024 | sg.finance.yahoo.comHookipa Pharma Reports Q3 Earnings Amid Strategic ChangesNovember 16, 2024 | markets.businessinsider.comHOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business UpdatesNovember 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK) and SCYNEXIS (SCYX)November 12, 2024 | markets.businessinsider.comHOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-BreakerNovember 12, 2024 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Hookipa Pharma (HOOK)November 12, 2024 | markets.businessinsider.comHOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-BreakerNovember 11, 2024 | globenewswire.comHOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024October 31, 2024 | globenewswire.comPositive Outlook on Hookipa Pharma Driven by Clinical Advancements and Active Scientific EngagementOctober 30, 2024 | markets.businessinsider.comHookipa Pharma doses first patients with eseba-vecOctober 30, 2024 | markets.businessinsider.comHOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck CancerOctober 30, 2024 | globenewswire.comHOOKIPA Pharma to Present Strong Preclinical HB-700 DatasetSeptember 24, 2024 | globenewswire.comHOOKIPA Pharma (NASDAQ:HOOK) Stock Quotes, Forecast and News SummarySeptember 11, 2024 | benzinga.comHOOKIPA Pharma Announces Board of Directors ChangesAugust 30, 2024 | globenewswire.comHOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 28, 2024 | globenewswire.comHookipa Pharma Inc (NASDAQ:HOOK) Short Interest UpdateHookipa Pharma Inc (NASDAQ:HOOK - Get Free Report) saw a large drop in short interest during the month of August. As of August 15th, there was short interest totalling 26,800 shares, a drop of 71.3% from the July 31st total of 93,400 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily volume of 51,600 shares, the short-interest ratio is currently 0.5 days.August 27, 2024 | marketbeat.comHOOKIPA Pharma Second Quarter 2024 Earnings: Revenues Miss ExpectationsAugust 11, 2024 | finance.yahoo.comBuy Rating and Price Target Increase for Hookipa Pharma Amid Clinical and Financial ProgressAugust 10, 2024 | markets.businessinsider.comHOOKIPA Pharma Inc.: HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 10, 2024 | finanznachrichten.deSquamous Cell Carcinoma Drugs Pipeline 2024 | Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, ModernaAugust 10, 2024 | theglobeandmail.comHOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 10, 2024 | finance.yahoo.comHOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 8, 2024 | globenewswire.comBuy Rating Affirmed for Enanta Pharmaceuticals Amid Promising Clinical Developments and Robust Financial HealthAugust 6, 2024 | markets.businessinsider.comHookipa Pharma Inc (NASDAQ:HOOK) Short Interest Up 47.1% in JulyHookipa Pharma Inc (NASDAQ:HOOK - Get Free Report) was the target of a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 95,300 shares, a growth of 47.1% from the June 30th total of 64,800 shares. Based on an average daily volume of 86,400 shares, the short-interest ratio is presently 1.1 days. Currently, 1.2% of the company's stock are sold short.July 29, 2024 | marketbeat.com Get Hookipa Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter. Email Address HOOK Media Mentions By Week HOOK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HOOK News Sentiment▼0.000.60▲Average Medical News Sentiment HOOK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HOOK Articles This Week▼31▲HOOK Articles Average Week Get Hookipa Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alto Neuroscience News Today Skye Bioscience News Today Immunic News Today Citius Oncology News Today Galectin Therapeutics News Today Inozyme Pharma News Today IGM Biosciences News Today Tiziana Life Sciences News Today Adlai Nortye News Today Assembly Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HOOK) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hookipa Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hookipa Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HOOK Stock Alerts